AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05868226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALX148
Description: CD47 Inhibitor: A fusion protein containing a high affinity engineered D1 domain of human signal regulatory protein alpha (SIRPα) variant 1 (v1) genetically linked to a modified and inactive Fc domain of human immunoglobulin (Ig) G1.
Study NCT05868226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fam-Trastuzumab Deruxtecan-Nxki
Description: Antibody-drug conjugate (ADC): A recombinant humanized anti-human HER2 IgG1 monoclonal antibody, conjugated with linker to a Topoisomerase I inhibitor
Study NCT05868226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanidatamab
Description: Bispecific HER2 antibody: A humanized, bispecific, immunoglobulin G isotype 1 (IgG1)-like antibody directed against the juxtamembrane extracellular domain (ECD4) and the dimerization domain (ECD2) of human epidermal growth factor receptor 2 (HER2).
Study NCT05868226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: Small molecule tyrosine kinase inhibitor (TKI) of HER2 (oral drug).
Study NCT05524428 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Implementation Science Strategy
Description: The investigators will be conducting focus groups and identifying barriers and facilitators, and the investigators will be matching identified barriers and facilitators to implementation strategies at the patient, provider, and system level which the investigators will be testing using rapid-cycle methods.
Study NCT04651595 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Caudal block
Description: caudal block with low dose bupivicaine 0.25% to preserve tone
Study NCT04651595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: morphine to control pain and avoid using muscle relaxant
Study NCT05269992 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real food products
Description: As per arm/group descriptions.
Study NCT05388812 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual Vocational Rehabilitation (TAU-VR)
Description: TAU-VR Services may include 1) Compensated Work Therapy-Transitional Work (CWT-TW) assignment in a set-aside, minimum-wage, short-term job, typically in the VA setting (approximately 50% of the Veterans randomized to TW in past studies conducted by the investigators actually engaged in TW assignment) or 2) CWT-Community-Based Employment Services (CWT-CBES) which involves a community job search, placement in a competitive job, with limited follow-along support that typically ends after the Veteran is working in his/her first job
Study NCT05388812 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Description: The IPS model involves the following important domains: competitive employment, eligibility based on client choice of employment, integration of IPS and treatment team personalized counseling, rapid job search, systematic job development, and time-unlimited and individualized support.
Study NCT06347926 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Questionnaires given before and after photobiomodulation
Description: Questionnaires given at 1 month, 6 months and 12 months
Study NCT05559463 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ITIS diet
Description: anti-inflammatory (ITIS) diet for 28 days
Study NCT05348837 — intervention group
Intervention type: PROCEDURE
Intervention: Deep brain stimulation
Description: Candidacy for DBS implantation will be determined by the treating team, which includes a neurologist, neurosurgeon, neuropsychologist, neuro-radiologist, and palliative care physician.
Study NCT06097845 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transcranial Ultrasound
Description: Patients who underwent reconstructive sonolucent cranioplasty will receive standard of care postoperative imaging (i.e. CT, MRI) in addition to ultrasound imaging. Ultrasound imaging will be performed by clinicians using FDA-approved ultrasound devices (GE Venue Go, Fujifilm Sonosite X-Porte, GE Volusion E10 and Clarius HD3 etc.) currently used in routine clinical practice.
Study NCT05429697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMT-NK inj.+Pembrolizumab
Description: SMT-NK inj. will be administered as an intravenous (IV) infusion on Day 1,Day 7 of each 21-day cycle.~Pembrolizumab will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
Study NCT05429697 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
Study NCT06638775 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fesia Grasp
Description: The Fesia Grasp device is based on the superficial electrical stimulation of the forearm musculature to provoke flexion and extension movements of the wrist, thumb, index finger and fingers 3, 4 and 5.
Study NCT06638775 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GLOBUS ELITE
Description: is an electro-stimulator designed for sport and fitness, but with special attention also for beauty treatments thanks to the new sequential stimulation currents, excellent for their draining effects.
Study NCT06638346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shortened FIFA 11+ warm-up exercise program
Description: The shortened FIFA11+ incorporates 5 exercises from the original FIFA11+ part 2 and 3: Sideways bench, single-leg stance, squats, jumping and plant and cut (refer to FIFA 11+ manual). All exercises, except plant and cut, have three levels of difficulty. Difficulty progression will follow FIFA11+ guideline option C where all players progress to the next level of all exercises after 3 or 4 weeks. This program is done on artificial turf.~Coaches will be trained on FIFA guidelines by the primary investigator and provided with explanatory placards and the FIFA 11+ manual. The primary investigator will conduct checks twice a week with the coaches to address any questions and review the program. Only the shortened FIFA11+ group will receive verbal feedback as per FIFA11+ guidelines.
Study NCT06638346 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brazilian warm-up exercise program
Description: The control group engages in a Brazilian warm-up. The warm-up consists of exercises performed in standing and while running including the following:~* Performed in standing: Circular Arms (20-30 sec total), Opening and closing of the hips (20-30 sec total).~* Performed while running back and forth on the field: Jogging (2 times), high kicks (2 times), glute kicks (2 times)~* Performed while running forward (exercise), then small jog back without performing the exercise: hand-to-heel touches (2 times), knee and heel touches (2 times each side), side leg swings (2 times) and progressive sprint 80-90% speed (2 times).~Coaches will supervise the session but will not be allowed to give verbal feedback. This program is done on artificial turf.
Study NCT05371379 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM338 Injection
Description: A humanized monoclonal antibody.
Study NCT05371379 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: CM338 Injection
Description: A humanized monoclonal antibody.
Study NCT06643572 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality simulator
Description: This virtual reality simulator allows for the simulation of a lumbar transforaminal epidural steroid injection using the patient's 3D lumbar images.
Study NCT04892277 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563
Description: Given IV
Study NCT04892277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Given IV
Study NCT04892277 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood and tissue samples
Study NCT04892277 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration
Study NCT04892277 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study NCT04892277 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT04892277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT04892277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study NCT04892277 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04892277 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo CT/PET
Study NCT05078112 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sleep sensor technology
Description: Infants will sleep on a novel device with built-in sensor technology that tracks sleep patterns and provides output to soothe them to sleep. The device will give this output for first 10 nights, then wean the output the child receives over 10 nights.
Study NCT05645380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: AUC=6, IV
Study NCT05645380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75 mg/m2, IV
Study NCT05645380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 60 mg/m2, IV
Study NCT05645380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 600 mg/m2, IV
Study NCT05645380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: 200 mg, IV
Study NCT04558736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin (Rabbit)
Description: Given intravenously (IV)
Study NCT04558736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given intravenously (IV)
Study NCT04558736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given intravenously (IV)
Study NCT04558736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Given intravenously (IV)
Study NCT04558736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Filgrastim is a human granulocyte colony-stimulating factor (G-CSF), produced by recombinant DNA technology. Dosage and Route of Administration: 5mcg/kg subcutaneous or intravenous daily until ANC >2000 for 2 consecutive days, or as clinically indicated
Study NCT04558736 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Lymphoid Irradiation (TLI)
Description: TLI will be given at 800 cGy total dose in 4 fractions.
Study NCT04558736 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS
Description: The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
Study NCT04558736 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPC, A Infusion
Description: Given intravenously Day 0-HPC, A Infusion (TCR αβ+/CD19+-depleted graft)
Study NCT04558736 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD45RA-depleted DLI
Description: CD45RA-depleted DLI will be given at least ONE week after engraftment
Study NCT06567548 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: An absorbable gelatin sponge is a sterile hemostatic agent primarily composed of purified porcine-derived gelatin. It is widely utilized in surgical procedures to control bleeding
Study NCT06567548 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Platelet-rich fibrin (PRF)
Description: Platelet-rich fibrin (PRF) is a biomaterial derived from the patient's own blood, utilized primarily in regenerative medicine and surgery due to its rich content of growth factors and its ability to promote healing.
Study NCT06567548 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Albumin Platelet Rich- Fibrin
Description: is an innovative biomaterial that combines the regenerative properties of platelet-rich fibrin (PRF) with the structural and functional benefits of albumin. This mixture is designed to enhance tissue healing and regeneration by utilizing autologous blood components.
Study NCT05052684 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leaflex™ Performer
Description: A transfemoral catheter designed to treat calcific aortic stenosis by scoring the calcification in the aortic valve leaflets.
Study NCT06529484 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warm Water Foot Bath Intervention
Description: Participants will take a warm water foot bath at 38-40ºC for 20 minutes nightly for 7 days.
Study NCT06122948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The midazolam group
Description: The midazolam group will receive intranasal midazolam (0.1 mg/kg)
Study NCT06122948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The midazolam ketamine group
Description: the midazolam ketamine group will receive intranasal midazolam (0.1mg/kg) and ketamine (3mg/kg)
Study NCT06460532 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baseline treatment
Description: Transcutaneous Electric Nerve Stimulation (TENS) of Care Vision company will be applied, with a pulse duration of 250 microseconds at a frequency of 80 Hz for 15 min in the suboccipital region and the trapezius bilaterally.
Study NCT06460532 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Baseline treatment
Description: Transcutaneous Electric Nerve Stimulation (TENS) of Care Vision company will be applied, with a pulse duration of 250 microseconds at a frequency of 80 Hz for 15 min in the suboccipital region and the trapezius bilaterally.
Study NCT05765175 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Varian Cardiac Radioablation (CRA)
Description: Subjects randomized to CRA will be treated with the Varian CRA system according to a uniform CRA protocol. A dose of 25 Gy in a single fraction is prescribed to the planning target volume (PTV), and delivered using a stereotactic body radiotherapy (SBRT) technique.
Study NCT05765175 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter Ablation (CA)
Description: Subjects randomized to the CA arm will be treated according to a uniform CA protocol.
Study NCT05329831 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured training using telehealth
Description: The intervention is based on self-care activities. Self-care states that people have an innate ability to take care of themselves.
Study NCT05456087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: incobotulinumtoxin A
Description: Up to 150 units of incobotulinumtoxin A will be injected at up to 30 injection sites within the hair loss area
Study NCT06570252 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: activated Light Source (aPDT)
Description: Application of SW3100 Formulation (0.2% chlorhexidine gluconate and methylene blue) in both nostrils followed by placing the SW3200 Nasal Light Illuminator with one channel per nostril.~Activation of SW4000 Light Source (Class 1 Laser Device) that generates red light consisting of 2 channels of 700 mW, 664 nm light (continuous wave) used to activate the disinfecting formulation.~Duration of illumination 2 minutes
Study NCT06570252 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: non activated Light Source (Control)
Description: Application of SW3100 Formulation (0.2% chlorhexidine gluconate and methylene blue) in both nostrils followed by placing the SW3200 Nasal Light Illuminator with one channel per nostril.~No activation of SW4000 Light Source~Waiting for 2 minutes
Study NCT06570200 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PMPR+iPRF
Description: locally applied iPRF in the periodontal pocket
Study NCT06570200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMPR+iPRF+Vit.D
Description: locally applied iPRF plus vitamin D in the periodontal pocket
Study NCT05667987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine administration
Description: General anesthesia with intravenous lidocaine administration
Study NCT06570200 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PMPR only
Description: scaling and root planing only will be done for the periodontal pocket for the control group
Study NCT04648085 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trigeminal Nerve Stimulation
Description: Applied to to the forehead using a self-adhesive electrode positioned bilaterally over the upper branches of the trigeminal nerve.The device generates electrical impulses allowing to stimulate the trigeminal nerve.
Study NCT05591365 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured In-Patient and Home plan
Description: A patient education session and a protocol comprise of 3 days. It consists of three different levels having progressive activities. The in-patient protocol will start from the day of the procedure. Each level contains 2 to 6 tasks, performed in sets of 5-10 repetitions 3 times a day. Home plan: Walking 3 days a week starting from normal pace ((RPE: 8-9) for10 minutes and progressively increased intensity and duration over the period of 12 weeks (RPE: 13-14).
Study NCT05591365 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional Therapy
Description: In-Patient: Wound care, Bed mobility:~AROMS (10 Reps\*3sets\*TD), Breathing Exercise (10 Reps\*3sets\*TD), Mobilization (Walk as per patient tolerance) Patient Education: To keep the heart healthy Diet Avoid strenuous exercise and lifting heavy objects Avoid valsalva manure, Quit smoking Lower cholesterol levels, Maintain a healthy weight Control other conditions, such as diabetes and high blood pressure Take medications as prescribed by your doctor Get regular exercise: Walking at a normal pace as per tolerance (RPE up to 10)
Study NCT05748769 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Practice (UL)
Description: Subjects performed RMs toward the units that were activated in the same order as the tested sequence 1-4-3-5-4-2, and with an activation duration and delay of 1 s. The practice included 16 blocks, each consisting of 30 RM with a 30 s pause after each block
Study NCT05748769 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Observation (SO)
Description: Subjects observed the illuminating switches while avoiding moving. The subjects observed RMs toward the units that were activated in the same order as the practiced sequence 1-4-3-5-4-2, also with an activation duration and delay of 1 s and 30 s pause after each block.
Study NCT05748769 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nature Observation (NO)
Description: The video-clip consisted of a 16 min nature movie in cycles of one-minute observation and pausing 30 s, equivalent to the timing of RMs performed by groups UL and SO
Study NCT06445023 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: barzolvolimab
Description: Subcutaneous Administration
Study NCT06445023 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Matching placebo Subcutaneous Administration
Study NCT06608849 — intervention group
Intervention type: OTHER
Intervention: Blood samples
Description: Blood sampling for proteomics and transcriptomics, suPAR measurement \&amp; isolation and stimulation of peripheral blood mononuclear cells, eGFR, serum creatinine, cystatin c \&amp; urea
Study NCT06608849 — intervention group
Intervention type: OTHER
Intervention: Six-minute walk test, Spirometry, HRCT, Heart ultrasound, Completion of questionnaires of symptoms
Description: Spirometry for forced expiratory volume in the first, second, total lung capacity and diffusion capacity of carbon monoxide.
Study NCT05576337 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 16 weeks of strength training protocol
Description: 16 weeks of strength training protocol
Study NCT06591741 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Oral PCA
Description: PCA 1,000 mg BID until surgery, held until anticoagulation, and resumed at 1,000 mg daily for 4 years
Study NCT06674564 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc Acetate 50 Mg Oral Capsule
Description: zinc suppose to improve immunity and wound healing after laryngectomy
Study NCT06674564 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: probiotics lowering infections rates and improving outcomes after surgery
Study NCT05997082 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness Self-Compassion Course
Description: This course is designed to reduce burnout and compassion fatigue among specialist rehabilitation providers. Course materials are adapted from the Center for Mindful Self-Compassion (CMSC).